supporting life after GLP-1 — with science.
GLP Keeper exists because the hardest part of the GLP-1 journey isn't losing the weight. It's keeping it off.
the problem we solve
GLP-1 receptor agonists like Ozempic, Wegovy, Mounjaro, and Zepbound are remarkably effective at reducing body weight. Clinical trials show 15–22% average weight loss. But the data that follows is less discussed: after stopping the medication, patients regain approximately two-thirds of their lost weight within 12 months.
This isn't a failure of willpower. It's biology. GLP-1 medications work by altering appetite signaling, gastric emptying, and metabolic pathways. When the medication stops, those systems revert — and without structured support, the weight returns.
GLP Keeper provides that structure.
what GLP Keeper does
Daily Tracking in 30 Seconds
Log your weight, protein intake, activity, and how you're feeling — all in under 30 seconds. Consistency matters more than detail. GLP Keeper is designed for daily habits, not data entry marathons.
AI-Powered Pattern Recognition
Our AI analyzes your daily logs to surface patterns you might miss: correlations between sleep and appetite, protein intake trends, early warning signs of rebound. Insights are delivered as gentle nudges, never judgments.
Visual Progress Tracking
Track body composition changes with photo progress, weight trend charts, and body measurement history. See the full picture — not just the number on the scale.
Science-Based Risk Assessment
Your rebound risk score is calculated from clinical trial data — not generic formulas. It accounts for your medication history, rate of weight loss, protein intake, exercise habits, and time since discontinuation.
our clinical foundation
Every algorithm, risk score, and recommendation in GLP Keeper is grounded in published, peer-reviewed research. We don't make claims we can't cite.
STEP 1 Trial (NEJM, 2021)
The foundational semaglutide trial. 1,961 participants. Demonstrated 14.9% weight loss and subsequent regain patterns after discontinuation that inform our rebound risk models.
SURMOUNT-1 Trial (NEJM, 2022)
The landmark tirzepatide trial. 2,539 participants. Up to 22.5% weight loss at the highest dose. Body composition data informs our lean mass preservation recommendations.
Cambridge Meta-Analysis (2024)
Systematic review of weight regain across multiple GLP-1 discontinuation studies. Provides the statistical foundation for our week-by-week timeline projections.
ACE Fitness & Endocrine Society Guidelines
Clinical practice guidelines for protein intake, resistance training, and body composition monitoring during pharmacological weight loss. Directly informs our daily targets.
our principles
Science first. Every feature is backed by published clinical data. We cite our sources. When the evidence is uncertain, we say so.
Zero judgment. Weight regain after GLP-1 discontinuation is a biological response, not a character flaw. Our tone is supportive, factual, and never shaming.
Privacy by default. Your health data is yours. We encrypt everything, sell nothing, and delete on request. No ads, no data brokers, no exceptions.
Not medical advice. We are a wellness tool. We never recommend medication changes. We always direct users to their healthcare providers for clinical decisions.
try our free tools
⚕️ GLP Keeper is a wellness tool, not medical advice. Always consult your healthcare provider.